1. Scrip

DREAMM Data Sets GSK’s Blenrep Up For Second Line Myeloma Dominance

 
• By Andrew McConaghie

Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.

New GSK sign
• Source: Shutterstock

Once almost written-off, GSK’s Blenrep now looks like a practice-changing therapy for patients with relapsed/refractory multiple myeloma, after the company unveiled impressive Phase III overall survival data at the American Society of Hematology (ASH) meeting in San Diego, CA.

GSK now believes that Blenrep (belantamab mafodotin), once re-approved, could not only displace Johnson & Johnson/Genmab’s Darzalex as standard of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.